OR WAIT 15 SECS
A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers.
Accenture has agreed to acquire Octagon Research Solutions. Read More
FDA has issued a Complete Response Letter to Baxter International for HyQ, an investigational combination immunoglobulin product for treating primary immunodeficiencies. Read More
DKSH has agreed to divest OLIC, a CMO to Fuji Pharma. Read More
Bristol-Myers Squibb has announced the expiration of the Hart-Scott-Rodino waiting period for its acquisition of Amylin Pharmaceuticals. Read More
GlaxoSmithKline has completed its $3.6-billion acquisition of Human Genome Sciences. Read More
Isis Pharmaceuticals has successfully completed a pre-approval inspection by EMA of its manufacturing facility in Carlsbad, California, thereby allowing Isis to supply Genzyme with mipomersen sodium, the drug substance in Kynamro. Read More
Johnson & Johnson has discontinued Phase III clinical development of bapineuzumab intravenous (IV), a drug to treat mild-to-moderate Alzheimer’s disease and will take a charge of between $300 million and $400 million in the third quarter 2012. Read More
NIH National Institute of Allergy and Infectious Diseases (NIAID) has awarded Advanced BioScience Laboratories a contract to provide NIAID with preclinical development and cGMP manufacturing support for multiple vaccine and biologic products identified by NIAID program staff. Read More
Sanofi and Regeneron Pharmaceuticals have received FDA approval for their a new biologic drug, Zaltrap (ziv-aflibercept) for use in combination with a FOLFIRI (folinic acid, fluorouracil, and irinotecan) chemotherapy for treating colorectal cancer. Read More
ViroPharma has received FDA approval for industrial-scale manufacturing of Cinryze (C1 esterase inhibitor [human]), a nanofiltered plasma-derived C1 esterase inhibitor product.
Advantar Laboratories has named Dave Bergstrom as chief operating officer. Read More
Cytovance Biologics has appointed Don Wuchterl as senior vice-president of manufacturing operations. Read More
Teva Pharmaceutical has appointed Carlo De Notaristefani as president and CEO of global operations, and Aharon (Arik) Yaari as executive vice-president of community and institutional affairs. Read More
Related Content:PharmTech News